Phase 1 N=19 Behavioral Effects of Drugs: Inpatient (36) (Alcohol, Duloxetine, and Methylphenidate)
Alcohol Use Disorder
Primary: Reinforcing Effects (Pre-Alcohol Dose Consumption) — 0.005; .01; 0.007; 0.005 Units on a Theoretical Scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=8 Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
Methamphetamine Use Disorder
Primary: Reinforcing Effects of Methamphetamine Following Methylphenidate (0 mg; Placebo) Maintenance. — 0; 0; 3.33; 7.25 Trials Completed
Phase 1 N=11 The Behavioral Effects of Opioids and Alcohol
Opioid Use · Alcohol Drinking
Primary: Peak Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 12.9; 47.1; 49.9; 54.8 score on a scale
Phase 1 N=11 Prescription Medication Interactions
Opioid Use · Sedative Use
Primary: Change in Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 7.40; 39.00; 40.80; 24.50 Score on a scale — p=<0.0001
Phase 2 N=24 The Effect of Prescription Medications in Marijuana Users
Marijuana Abuse
Primary: Peak Effect of Marijuana Withdrawal — 4.6; 4.1; 2.9; 1.7 units on a scale
Early Phase 1 N=138 Drugs Brain and Behavior (DDP)
Stimulant Use
Primary: Change in SUbjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 19.2; 57.8…
Phase 1 N=36 Effect of Stimulant Drugs on Social Perception
Healthy · MDMA ('Ecstasy')
Primary: Responses to Affective Touch — -1.24; 0.12; 0.19; 0.25 units on a scale
N/A N=28 Individual Differences in the Response to Drugs
Healthy
Primary: Change in General Drug Effects (Drug Effects Questionnaire) at 30 Minutes After Capsule Administration — 4.79; 12.83; 11.08; 12.17 units on a scale
Early Phase 1 N=30 Behavior Brain Responses
Alcohol Drinking · Drinking Behavior · Physiological Effects of Drugs
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire Across Sessions…
Early Phase 1 N=22 Effects of Drugs on Responses to Brain and Emotional Processes
Autism Spectrum Disorder · Healthy
Primary: Change in Responses to Affective Touch — 3.01; 4.06 units on a scale
Early Phase 1 N=30 Behavioral Effects of Pregabalin and Cannabis
Cannabis-use Disorders
Primary: Number of Self-administered Puffs of Smoked Cannabis Containing Active THC Concentrations Compared to Placebo Under Controlled Laboratory Conditions — 2.00; 2.67; 3.60…
Phase 1 N=8 Reinforcing Effects of Marijuana and Opioids
Marijuana Use · Opioid Use
Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units
Phase 1 N=10 Marijuana Effects on Simulated Driving Performance
Cannabis · Cannabis Use · Marijuana
Primary: Mean Peak for Standard Deviation in Lane Position (SDLP) — 1.33; 1.37; 1.42; 1.35 centimeters
Phase 2 N=23 Caffeine and Cocaine
Cocaine Dependence
Primary: Visual Analog Scale Subjective Rating of Drug Effects — 8.65; 9.85; 13.65; 10.43 units on a scale
N/A N=65 Effects of MDMA on Social and Emotional Processing
Drug Addiction
Primary: Emotional Recognition (MDMA) — 55.9 percent intensity
Phase 4 N=133 Interactions Between Drug Effects and Environments II
Substance-Related Disorders
Primary: Change in Time Spent in Drug-paired Room — 24.5; 6.2 seconds
Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale
Phase 4 N=18 Opiates and Benzodiazepines on Driving
Driving Behavior
Primary: SDLP — 35.2; 49.8; 50.0; 33.5 centimeters
Phase 1 N=25 Effects of Commonly Used Medications on Mood and Choice
Healthy
Primary: Participant Subjective Ratings of Drug Liking (Peak Change) — 1.00; -0.11; 0.88; 0.33 score on a scale
Phase 2 N=21 Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
Marijuana Abuse
Primary: Marijuana Use — 2.5; 3.9 Reported uses per day
Phase 2 N=10 The Effects of Sedatives on Tobacco Use Disorder
Tobacco Use Disorder
Primary: Side Effects — 1.3; 1.4 score on a scale
Phase 2 N=10 Genetic Effects on Dopamine Response to an Opiate
Polymorphism-Genetic · Pain · Addiction
Primary: 11C Raclopride Binding Potential in Caudate — 3.25; 3.45 mCi/ml
Early Phase 1 N=24 Effects of Flavors on Nicotine Reinforcement in Smokers
Nicotine Dependence
Primary: The Reinforcing Drug Effects Will be Measured With the Drug Effects Questionnaire (DEQ). — 43.18; 26.22; 25.20; 56.00 units on a scale
Phase 2 N=23 Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana
Marijuana Smoking
Primary: Subjective Marijuana Effects — 13; 15; 16; 16 units on a scale (0-100mm)
Phase 1 N=93 Differential Responses to Drugs and Sweet Tastes
Bipolar II Disorder
Primary: Change in Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Sub-scales of Drug Effects Questionnaire (DEQ). — 18.88…
Phase 2 N=18 The Effect of Glutamatergic Modulation on Cocaine Self-administration
Cocaine Dependence
Primary: Number of Choices to Self-administer Cocaine (Out of 5 Choices) — 1.61; 4.33 number of cocaine choices
Phase 1 N=10 Opioid and Cannabinoid Interactions
Marijuana Usage · Opioid Use
Primary: Change in Subject-Rated Outcome - VAS Drug Liking — 3; 53.33; 58.89; 38.78 score on a scale
N/A N=127 Cocaine Use Reduction and Health
Cocaine Use Disorder
Primary: Endothelin-1 Levels — 2.15; 2.063; 1.956 pg/ml
Phase 2 N=20 The Discriminative Effects of Tramadol in Humans
Opioid Abuse · Opioid Addiction · Stimulant Abuse
Primary: Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test — 87; 87.5; 90 percent of correct response
Phase 2 N=13 Persisting Effects of Psilocybin
Healthy
Primary: Amygdala Response to Stimuli in the Emotion Recognition Test — 0.835; -0.759; 0.619; 0.503 BOLD percent signal change